Oncology PracticeCommunity practice lung cancer patients insufficiently tested for treatment-related biomarkersJune 6, 2021Lung CancerASCO Lung Cancer
Oncology PracticeNSCLC: Immune-related AEs during checkpoint inhibitor therapy may predict outcomesJune 6, 2021Lung CancerASCO Lung Cancer
Oncology PracticeDrug combo disappoints as second-line therapy for advanced NSCLC with EGFR and T790M mutationsJune 1, 2021Lung Cancer
Oncology PracticeFirst drug for lung cancer with KRAS mutation gains FDA approvalJune 1, 2021Lung Cancer
Oncology PracticeImmunotherapy takes first major step into earlier NSCLCMay 24, 2021Lung CancerASCO Lung Cancer
Oncology PracticeThe power and promise of social media in oncologyMay 3, 2021Patient & Survivor CareBreast CancerCNS/Brain CancerGastrointestinal CancerGenitourinary CancerGynecologic CancerHead & Neck/Thyroid Cancers
Oncology PracticeHyperprogression on immunotherapy: When outcomes are much worseApril 30, 2021ImmunotherapyNonmelanoma Skin CancerMelanomaBreast CancerGastroenterologyGastrointestinal CancerGenitourinary Cancer
Oncology PracticeSurvival benefit with nivolumab extends to 5 years in NSCLCApril 26, 2021Lung Cancer
Oncology PracticeLeveraging the microbiome to enhance cancer treatmentApril 16, 2021MelanomaLung Cancer
Oncology PracticeNew data dim hopes for ‘triumph of drug discovery’April 14, 2021Patient & Survivor CareLung CancerGastrointestinal Cancer
